Research Triangle Park resurgent with billions in investment in biotechnology manufacturing. With a famous biotech cluster in Research Triangle Park (RTP) established almost 70 […]
BIO on the American Road visits pioneering NC biotech hub Read More »
For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters,
A national security priority: BIO pushes PAHPA reauthorization in 2026 Read More »
2026 was a busy year on the state level. Whether it was the expected healthcare policy priorities or newer ones, there was plenty to
Mid-year review: State-level legislative action impacting biotech Read More »
There was bipartisan support for the PASTEUR Act’s approach to addressing AMR and for NSCEB recommendations, both BIO priorities. A bipartisan Senate hearing sought
Senators seek solutions for AMR, maintaining US biotech leadership Read More »
What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A.
After 50 years of biotech, can AI help answer the next impossible question? Read More »
What will it take to build a stronger, more resilient U.S. life sciences industry? In a June 23 fireside chat at the 2026 BIO
BIO 2026: Gov. Tina Kotek on Oregon’s thriving bioscience sector Read More »
Gary Sinise, Marcus Freeman, and BIO President & CEO John F. Crowley discussed leadership, resilience, and purpose at BIO 2026, drawing lessons from military
BIO 2026: Gary Sinise, Marcus Freeman on leadership, service, and resilience Read More »
Industry, academic, and policy leaders at BIO 2026 discussed how federal research funding, private investment, and public-private partnerships can strengthen the U.S. biopharma ecosystem
From drug discovery to target identification, biotech leaders explored where AI is delivering results today, why data quality matters, and how companies can successfully
BIO 2026: Where AI is delivering – and where biotech must go next Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
